Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06475898

Longitudinal Endpoint Assessment of Disease Burden in HD

Status
Recruiting
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
Huntington Study Group · Network
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.

Detailed description

The LEAD-HD study will be offered via HSG's online observational research platform called myHDstory®. This direct to patient study will collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD in a 24-month longitudinal natural history study that participants complete at any time and with their own electronic device.

Conditions

Timeline

Start date
2024-06-25
Primary completion
2026-12-01
Completion
2026-12-01
First posted
2024-06-26
Last updated
2025-09-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06475898. Inclusion in this directory is not an endorsement.

Longitudinal Endpoint Assessment of Disease Burden in HD (NCT06475898) · Clinical Trials Directory